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Physician Awareness and Adherence to Clinical Practice
Guidelines in the Diagnosis of Vaginitis Patients:
A Retrospective Chart Review
Paul Nyirjesy, MD,1 Wendy M. Banker, MPA,2 and Tiffany M. Bonus, MS3
Abstract
Vaginitis is one of the main causes of primary care and gynecological visits in the United States. The most
common infectious causes are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis.
A physician survey was conducted to measure awareness of vaginitis clinical guidelines and availability of in-
office point-of-care (POC) diagnostic tools. Participants were asked to perform a chart review to evaluate
diagnostic practices for their symptomatic vaginitis patients. A total of 333 physicians and 984 patient charts
were included. Physicians were most familiar with VVC and BV diagnostic guidelines; fewer than half were
aware of current trichomoniasis guidelines. Although access to POC tools used to evaluate and diagnose
vaginitis varied by practice, there was limited access to all 3 tools (microscope, pH test strips, potassium
hydroxide solution) required to perform a full Amsel workup for BV (47% obstetricians/gynecologists vs. 32%
primary care physicians, P < .05). Based on guidelines, 66% of patients evaluated for VVC, 45% of patients
evaluated for BV, and 17% evaluated for trichomoniasis received an optimal workup. Among trichomoniasis
positive patients, 75% received chlamydia/gonorrhea testing, 42% were tested for HIV, partner therapy was
noted in 59% of cases, and 47% returned to be retested within 3 months. Limited awareness of recommended
diagnostic practices and lack of access to POC tools contributed to broad guideline nonadherence. This study
demonstrates that clinicians commonly fall short of current guidelines and suggests the need for lab-based
assessments and appropriate insurance coverage to fill the present diagnostic void.
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Introduction
The most common gynecologic-related diagnosis
1 in the
primary care setting, vaginitis is also one of the most
widespread causes for patient visits to obstetrician/gynecolo-
gists (OBGYN).2 Infectious vaginitis is generally caused by
bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), or
trichomoniasis.3,4 Clinically, vaginitis patients may present with
1 or more troublesome symptoms, including abnormal vaginal
discharge, odor, pruritis, discomfort, and pain.5 Symptoms can
be nonspecific and vary by patient.
Clinical guidelines recommend that BV be diagnosed using
Amsel’s criteria,2,6,7 which are based on presence of 3 or 4
of the following: a homogeneous, thin, white-gray vaginal
discharge; a vaginal pH of >4.5; clue cells on saline mi-
croscopy; and a positive potassium hydroxide (KOH) whiff
test. In research settings, Nugent criteria, which utilize lab-
oratory examination of the Gram stain, are considered the
gold standard for diagnosing BV.2,7,8 VVC is commonly
diagnosed through wet mount (KOH or saline) microscopy
or with a positive culture, which is more accurate than wet
mount alone.2,7 It is recommended that trichomoniasis be
diagnosed using nucleic acid amplification testing (NAAT),
which is far more sensitive at detecting T. vaginalis infec-
tions than is saline microscopy.2,7
An accurate vaginitis diagnosis can be hindered by sev-
eral factors within the physician’s practice. These include
subjective and possibly inaccurate clinician point-of-care
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(POC) in-office evaluations; diagnosis based only on as-
sessment of patient’s symptoms; and a lack of tools and
equipment, such as microscopes, to conduct a full patient
workup.9–11 The presence of mixed infections (2 or more of
BV, VVC, and trichomoniasis) or another sexually transmitted
infection (STI) can also make accurate diagnosis difficult.12–14
Although an appropriate vaginitis diagnosis is essential for
clinicians to prescribe the optimal treatment and reduce the
likelihood of persistence or recurrence, there is little published
information on the extent to which clinicians in nonacademic
practices adhere to current guidelines.
The primary objective of this study was to: (1) assess
current clinician practices in diagnosing patients with symp-
toms of vaginitis compared to the practices recommended in
clinical guidelines, (2) ascertain clinician awareness of vagi-
nitis clinical guidelines, and (3) assess the availability of di-
agnostic tools and equipment in the clinician’s office.
Methods
Study design
In order to address all research objectives, this study in-
cluded an online survey among physicians followed by online
patient chart review forms. The physician survey included
questions about their own knowledge and practices related to
the evaluation and diagnosis of vaginitis. Physicians then
completed the second portion of the survey, a retrospective
chart review of symptomatic vaginitis patients. This included
in-depth questions about longitudinal events from the patients’
initial presentation of symptoms to final diagnosis. The study
was piloted among 8 physicians, whose feedback was used to
enhance clarity of the survey instrument prior to large-scale
data collection. The Western Institutional Review Board de-
termined this study to be exempt from review as the research
was survey-based, and physician participants and their patient
charts were not identifiable.
Survey administration
The survey was administered online and completed by a
random sample of physicians from M3 Global Research’s
online panel, which includes more than 4 million health care
providers globally. Physicians identified in M3’s panel as
either an OBGYN or primary care physician (PCP) were sent
an email invitation to participate. In order to qualify, physi-
cians had to be in practice for 2 to 35 years, spend at least
70% of time on direct patient care, and have made at least 5
(OBGYN) or 3 (PCP) vaginitis diagnoses in the past month.
Physicians were excluded if they were not comfortable
pulling prior patient charts from their electronic health record
(EHR) system, based on International Classification of Dis-
eases (ICD)-9 or ICD-10 codes, or if they did not have at least
3 vaginitis patients who met study criteria. Physicians who
completed the study received $250 for their time.
Retrospective chart audit
Physicians were instructed to run a report within their
EHR that included patients seen at least 12 months prior to
survey completion and then chronologically go backward
through until they found a patient who was diagnosed with
BV, VVC, and/or trichomoniasis. Three patient charts were
pulled for study inclusion that met the following criteria:
age 18–64; presented with symptomatic vaginitis; received a
diagnosis of BV, VVC, and/or trichomoniasis at least 12
months prior to survey completion; and was seen by the
reporting physician within the past 12 months (for any
reason). Patients diagnosed with a malignancy within 3
years of the vaginitis presentation were excluded.
Data analysis
All data are unweighted. Results were analyzed using
SPSS version 25.0 statistical software (IBM Corp., Armonk,
NY); P < .05 was considered statistically significant. Ana-
lyses were exploratory in nature and reported using de-
scriptive statistics. Subanalyses were performed comparing
OBGYN and PCP practices and among patient charts to
compare vaginitis evaluation and diagnosis types.
Results
Respondent characteristics and demographics
In total, 4031 physicians were invited to this research,
1455 of whom entered the survey (36% response rate). Of
these, many did not complete the entire survey (393), did
not meet eligibility criteria (517), or entered the survey
after the desired number of completed interviews had been
achieved (205). The primary reasons for disqualification
were physician number of years in practice outside of the
study inclusion range (2 to 35) and low comfort level pulling
data from historical patient charts using ICD-9/ICD-10 codes.
In total, 340 physicians across the United States participated
in this research from October 29 to December 3, 2019. Survey
responses were reviewed throughout data collection, with 7
physician respondents removed because of poor data quality.
A total of 333 physicians (n = 248 OBGYNs and n = 85 PCPs)
were included in the final sample.
Each physician personally entered data for 3 patient charts,
for a total of 999 patients. Fifteen patients were asymptomatic
at the time of presentation, and thus were removed from the
study. The final analysis consisted of 984 vaginitis patients.
On average, the survey and chart audit instrument took 65
minutes to complete.
Physician and practice demographics
Table 1 presents physician demographic characteristics.
Overall, the physicians were well distributed in terms of
practice location, gender, and years in practice. Approximately
one quarter were PCP. More than half (56%, n = 185) of the
overall group described more than 40 evaluations for vaginitis
in a typical month. Sixty-three percent (n = 210) of physicians
indicated they work in a private/independent practice and were
not affiliated with a hospital.
Access to POC tools used to evaluate and diagnose vaginitis
varied by practice (see Table 2). There was limited access to all 3
in-office tools required to perform a full Amsel workup for a BV
diagnosis (47% OBGYN vs. 32% PCP; P < .05). Physicians with
2 to 14 years in practice were significantly less likely than those
with 15 to 35 years in practice to have access to a microscope
(56% vs. 74%; P < .05). Compared with OBGYNs, PCPs were
significantly more likely to have access to in-office commercial
test kits OSOM BVBLUE or OSOM Trichomoniasis rapid test
(Sekisui Diagnostics, Burlington, MA), and FemExam pH and
amines test card (Cooper Surgical, Shelton, CT).
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Physician understanding of guidelines
for the diagnosis of vaginitis
Overall, 85% (n = 212) of OBGYNs and 58% (n = 49) of
PCPs reported that they follow American College of Ob-
stetricians and Gynecologists (ACOG) guidelines for the
evaluation and diagnosis of vaginitis; 60% (n = 51) of PCPs
also referred to American Academy of Family Physicians
guidelines. Figure 1 illustrates the most common percep-
tions of recommended diagnostic modalities by diagnosis
type, which reflected perceived guidelines during the data
collection period (late October to early December 2019). All
data for this study were collected prior to the publication of
ACOG’s 2020 Practice Bulletin.2
For VVC, 84% (n = 281) recognized wet mount micros-
copy (saline or KOH) or culture as the recommended
practice (no significant difference by physician specialty).
Physicians were less likely to be aware of BV guidelines
(84% vs. 71%; P < .05). OBGYNs were significantly more
likely than PCPs to be aware that Amsel criteria or Gram
stain (Nugent criteria) are recommended in BV guidelines
(75% vs. 60%; P < .05). Physicians were least likely to be
aware of trichomoniasis guidelines that recommend NAAT
(84% and 71% vs. 45%; P < .05); there was no difference by
specialty in terms of trichomoniasis diagnostic guideline
awareness. More than half (53%, n = 177) of physicians
chose saline wet mount as the recommended diagnostic
practice for trichomoniasis.
Patient characteristics
Patient demographics are summarized in Table 3. Eighty-
seven percent of patients (n = 853) initially presented to their
current physician for vaginitis in 2018, while 8% (n = 81)
presented in 2017, and 5% (n = 50) in 2016 or before. Based
on physician-obtained history, 19% (n = 191) of patients
self-treated their vaginitis using at-home or over-the-counter
(OTC) medication and 29% (n = 281) of patients saw at least
1 other health care provider prior to their current physi-
cian for symptoms of vaginitis. Few patients (7%, n = 67)
had an unintended pregnancy within 6 months prior to their
vaginitis presentation.
At the time of initial vaginitis presentation, 21% of pa-
tients (n = 205) reported engaging in high-risk activities
within the preceding 3 months, which may or may not have
contributed to the onset of vaginitis. ‘‘High-risk’’ activities
were based on Centers for Disease Control and Prevention
(CDC) definitions of the term: a new sex partner, more than
1 sex partner, a sex partner with concurrent partners, a sex
partner who has an STI, or inconsistent condom use.7 Pa-
tients who were diagnosed with trichomoniasis were signif-
icantly more likely to report engaging in high-risk activities,
compared with patients who were not diagnosed with









South 30% (101)a 29% (73) 33% (28)
Northeast 24% (80) 26% (65) 18% (15)
West 24% (79) 23% (58) 25% (21)
Midwest 22% (73) 21% (52) 25% (21)
Gender
Male 51% (170) 48% (118) 61%* (52)
Female 49% (163) 52%* (130) 39% (33)
Years in practice
2–5 14% (48) 15% (37) 13% (11)
6–10 19% (63) 17% (41) 26% (22)
11–15 16% (52) 14% (35) 20% (17)
16–20 20% (67) 22% (54) 15% (13)
21–25 16% (52) 19%* (47) 6% (5)
26–35 15% (51) 14% (34) 20% (17)
Mean (SD) 15.7 (8.4) 16.0 (8.4) 14.9 (8.4)
Vaginitis patient volume b
1–10 5% (15) 2% (5) 12%* (10)
11–20 12% (40) 10% (25) 18% (15)
21–30 13% (42) 13% (33) 11% (9)
31–40 15% (51) 16% (39) 14% (12)
>40 56% (185) 59%* (146) 46% (39)
Mean (SD) 61.4 (53.3) 63.5 (54.4) 55.2 (49.7)
aValues in parentheses indicate the number of physicians who
selected each response choice, unless otherwise noted.
bNumber of patients presenting in prior month with suspected
bacterial vaginosis, vulvovaginal candidiasis, and/or trichomoniasis.
*Denotes statistical difference between specialties at P < .05.
OBGYN, obstetrician/gynecologist; PCP, primary care physician;
SD, standard deviation.
Table 2. Physician Access to Point-of-Care Diagnostics
Diagnostics Total (n = 333) OBGYN (n = 248) PCP (n = 85)
In-office tools
Potassium hydroxide (KOH) 66% (220)a 69%* (172) 56% (48)
Microscope 66% (219) 67% (167) 61% (52)
Vaginal pH test strips 59% (198) 62% (154) 52% (44)
In-office commercial tests
BD Affirm VPIII Microbial Identification Systemb 20% (65) 21% (51) 16% (14)
OSOM rapid kit (BVBLUE test, Trichomoniasis rapid test)c 14% (47) 10% (26) 25%* (21)
FemExam pH and amines test cardd 10% (33) 8% (19) 16%* (14)
aValues in parentheses indicate the number of physicians who selected each response choice.
bBecton, Dickinson and Company, Franklin Lakes, NJ.
cSekisui Diagnostics, Burlington, MA.
dCooper Surgical, Shelton, CT.
*Denotes statistical difference between specialties at P < .05.
OBGYN, obstetrician/gynecologist; PCP, primary care physician.
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trichomoniasis (41% vs. 17%; P < .05). Other demographic
differences between patients diagnosed with trichomoni-
asis compared with those who were not include: Black/Af-
rican American or Hispanic (54% vs. 36%; P < .05), single
relationship status (57% vs. 38%; P < .05), or those who had
Medicaid as their primary insurance (28% vs. 17%; P < .05).
Physicians ordered STI diagnostic laboratory testing for
39% (n = 385) of patients at the time of initial presentation.
STI lab testing included at least 1 of the following: chlamydia,
gonorrhea, HIV, syphilis, hepatitis B, human papillomavirus
(HPV), herpes simplex virus type 2 (HSV-2), or Mycoplasma
genitalium (Mgen). Patients were most likely to receive tests
for chlamydia (38%, n = 369) and/or gonorrhea (37%, n = 360),
followed by HIV (9%, n = 90) and syphilis (9%, n = 86).
Vaginitis diagnostic practices
Chart analysis showed that among all patients, 49%
(n = 486) were diagnosed based on point-of-care (POC)
assessment only, which was defined as at least one of the
following: vaginal pH, amine test, saline microscopy, KOH
microscopy, Gram stain (in-office), OSOM BVBLUE
or OSOM Trichomoniasis rapid test, or FemExam pH
and amines test card. In addition to or in lieu of POC
assessment, 22% (n = 217) received a BD Affirm test (DNA
Probe), 16% (n = 154) received NAAT, and 4% (n = 43)
received a vaginitis-related culture or Gram stain ordered
from a lab. Nine percent (n = 84) were diagnosed empiri-
cally, or based on an assessment of patient-reported symp-
toms only. See Figure 2 for POC assessments by suspected
vaginitis type.
Seventy-three percent (n = 714) of patient cases were
evaluated for VVC. Patients considered for VVC had evalu-
ations of vaginal discharge (99%, n = 705) and 64% (n = 459)
were assessed with wet mount microscopy (saline or KOH).
Yeast culture was used less often (4%, n = 32). BD Affirm was
used in 25% (n = 179) and NAAT in 17% (n = 119) of patients.
Based on guidelines (saline or KOH microscopy, or yeast
culture), 66% (n = 468) of patients received a recommended
workup for VVC. OBGYNs were significantly more likely
than PCPs to perform a guideline-recommended workup (69%
of OBGYN charts vs. 53% of PCP charts; P < .05).
Seventy-eight percent (n = 763) of patient cases were
evaluated for BV. Among those patients, physicians per-
formed a full Amsel workup (all 4 criteria) in 18% (n = 135)
of patients, and 22% (n = 169) had 3 of 4 criteria assessed.
Nearly all had vaginal discharge evaluated (99%, n = 754).
Gram stain was used in 10% (n = 77). BD Affirm was used
FIG. 1. Physician-reported understanding of guidelines for modalities recommended to diagnose each type of vaginitis.
Each bar represents the proportion of physicians in total and by specialty who selected the recommended diagnostic studies
per vaginitis type. ‘‘Neither’’ or ‘‘NAAT not selected’’ represent the proportion of physicians who did not select a
guideline-recommended modality for the given vaginitis etiology. *Denotes statistical difference between specialties at
P < .05. KOH, potassium hydroxide; NAAT, nucleic acid amplification testing.
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in 25% (n = 190) and NAAT in 17% (n = 133) of patients.
Based on guidelines (at least 3 of 4 Amsel criteria or Gram
stain), 45% (n = 342) of patients received a recommended
workup for BV. OBGYNs were significantly more likely
than PCPs to perform a guideline-recommended workup
(50% of OBGYN patient charts vs. 28% of PCP patient
charts; P < .05).
Fifty-seven percent (n = 557) of patient cases were eval-
uated for trichomoniasis. As with other suspected diagnoses,
discharge was evaluated in 99% (n = 552) of those consid-
ered for trichomoniasis. Saline microscopy was used in 60%
(n = 334) of patients considered for trichomoniasis, while
BD Affirm was used in 24% (n = 132). Based on guidelines
regarding use of NAAT, 17% (n = 95) of patients received a
recommended workup for trichomoniasis (no significant
difference by physician specialty). Among patients evalu-
ated for trichomoniasis for whom physicians also noted
high-risk behaviors within 3 months of presentation, NAAT
use remained low (25%, n = 38 patient charts).
Across all patients, those who received NAAT as part of
their vaginitis workup were significantly more likely than
POC-only assessed patients to be Black/African American
(31% vs. 22%; P < .05), to have had an unintended preg-
nancy within the 6 months prior to presenting with vaginitis
(12% vs. 4%; P < .05), or to have reported high-risk be-
haviors within 3 months prior to their vaginitis presentation
(31% vs. 22%; P < .05).
Vaginitis diagnosis
At the initial vaginitis presentation visit, 93% (n = 919) of
patients received a diagnosis of BV, VVC, or trichomonia-
sis, with a 9% (n = 91) mixed-infection rate (2 or more of
BV, VVC, or trichomoniasis). Among patients who received
an initial POC diagnosis for which lab testing was ordered,
17% (n = 48) received a change in their vaginitis diagnosis
upon return of lab results. Most often, changes in diagnosis
were prompted by findings of a different etiology from the






(n = 162)(n = 402) (n = 526)
Age
18 to 24 25% (244)c 22% (90) 26% (137) 27% (44)
25 to 34 34% (332) 33% (132) 35% (184) 36% (59)
35 to 44 25% (244) 25% (101) 25% (131) 24% (39)
45 to 65 16% (164) 20% (79) 14% (74) 13% (20)
Mean (SD) 33.3 (10.9) 34.3 (11.5) 32.6 (10.3) 31.6 (10.1)
Ethnicity
White 52% (513) 55% (222) 51% (269) 43% (69)
Black or African American 23% (226) 18% (72) 24% (128) 29% (47)
Hispanic 16% (158) 17% (70) 15% (77) 25% (40)
Other 9% (78) 10% (36) 10% (47) 3% (5)
BMId
Underweight 1% (9) 1% (6) <1% (2) 1% (1)
Normal weight 38% (372) 39% (157) 39% (203) 40% (64)
Overweight 25% (248) 23% (93) 26% (139) 21% (34)
Obese 19% (184) 20% (79) 18% (94) 19% (30)
Relationship status
Single 41% (404) 35% (140) 42% (223) 57% (92)
Married/civil union 32% (314) 39% (155) 30% (156) 19% (30)
Long-term relationship 15% (144) 13% (53) 15% (80) 15% (25)
Divorced or widowed 6% (60) 7% (27) 6% (32) 5% (8)
Birth control usage 63% (616) 63% (255) 62% (325) 63% (102)
Pregnant
Yes 5% (52) 5% (22) 5% (25) 6% (10)
No 92% (910) 92% (369) 93% (490) 90% (146)
Not sure 3% (22) 3% (11) 2% (11) 4% (6)
Insurance type
Private 70% (690) 73% (292) 69% (365) 64% (104)
Medicaid 19% (184) 17% (67) 18% (94) 28% (45)
Other 11% (106) 10% (41) 13% (67) 9% (15)
aBased on information available in patient chart from initial presentation visit.
bCoinfection present in 11% of cases, as defined by a final diagnosis of more than 1 vaginitis condition. Given overlap due to coinfection,
statistical differences are not assessed between the final diagnosis groups.
cValues in parentheses indicate the proportion of patient charts that fit into each demographic characteristic, unless otherwise noted.
dUnable to assess patient BMI in 17% (n = 171) of patient cases because of missing height and/or weight data.
BMI, body mass index; BV, bacterial vaginosis; SD, standard deviation; VVC, vulvovaginal candidiasis.
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initial diagnosis, the addition of a trichomoniasis diagnosis
that had not been made prior to lab testing, or an added
mixed infection. Ultimately, 53% (n = 526) of patients were
diagnosed with BV, 41% (n = 402) with VVC, and 16%
(n = 162) with trichomoniasis. The mixed-infection rate was
11% (n = 110). A lower rate of mixed-infection was reported
among patients who received POC testing alone and did not
receive a molecular-based diagnostic test as part of their
workup, compared with those who received a molecular-
based test (8% vs. 15%; P < .05).
Trichomoniasis-specific follow-ups
Among patients diagnosed with trichomoniasis, 33%
(n = 52) of partners received treatment from a different health
care provider. Additionally, physicians provided a prescription
refill to 26% (n = 42) of their female patients for partner use.
Therefore, partner treatment was definitively noted in 59%
(n = 95) of cases. For one quarter (n = 40) of trichomoniasis
patients, the physician was unsure if the patient’s partner
received treatment.
Three quarters of trichomoniasis patients received chla-
mydia (n = 120) and/or gonorrhea (n = 121) testing, and 42%
(n = 68) were tested for HIV (either at initial presentation or
upon positive trichomoniasis lab test). Fewer than half (48%,
n = 77) returned to be retested for trichomoniasis within 3
months. Thirty-eight percent (n = 62) never returned to be
retested for trichomoniasis.
Discussion
By combining an online survey of physician knowledge
of guidelines and a chart review of patients undergoing as-
sessments for vulvovaginal complaints, this study sought to
evaluate physician understanding and implementation of
current guidelines. This study found that there were certain
vaginitis conditions for which physicians were well aware of
the guidelines but fell short of executing them and others for
which a large percentage of providers were unaware of
current recommendations. Differences in practice between
OBGYNs and PCPs also were noted in their methods of
evaluating vulvovaginitis complaints.
Physicians were most aware of VVC diagnostic guidelines,
regardless of specialty. Thus, it was not surprising that patients
evaluated for VVC were most likely to receive a guideline-
recommended workup of microscopy (saline or KOH) or
yeast culture. About one third of patients evaluated for VVC,
however, did not receive any guideline-recommended work-
up, and the test considered the most sensitive for VVC—yeast
culture—was seldom (4%) used. As has been emphasized by
FIG. 2. Data collected via patient charts for POC assessment used to make a vaginitis diagnosis based on suspected
vaginitis conditions. Each bar represents the proportion of patients in total for each vaginitis etiology evaluated. KOH,
potassium hydroxide; POC, point-of-care.
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other investigators, an inaccurate workup or reliance on pa-
tient symptoms alone can result in an incorrect or missed
VVC diagnosis10,11,15 or in the inappropriate use of OTC
products.16
Knowledge of BV diagnostic guidelines was lower, with
OBGYNs more likely to be familiar with the guidelines than
PCPs. Although widely available and inexpensive POC tools
can accurately diagnose BV in most cases,17 many practices
continue to lack access to all modalities required for a full
Amsel workup, as evidenced in this study and other published
literature.18,19 The finding that the absence of a microscope is
more common among physicians with 2 to 14 years in practice
versus those with 15 to 35 years in practice suggests a growing
generational shift among providers away from Amsel criteria.
More than half of patients (55%) evaluated for BV in this study
did not receive an optimal guideline-recommended workup
(Amsel or Gram stain). Potential overdiagnosis of BV may lead
to improper use of oral or vaginal antibiotics, which may have
unpleasant side effects (eg, nausea and dysgeusia) and can, in
turn, cause VVC.20 A missed or recurrent BV diagnosis can
result in lower quality of life.21–23
The study team is particularly concerned regarding the lack
of guideline awareness and adherence for trichomoniasis—the
most common non-viral STI in the United States.24 Patients can
have minimal symptoms or be asymptomatic,25–28 and the
sensitivity of a wet mount is approximately 50%–60%.2,7,29–31
Saline microscopy has therefore been de-emphasized in older
CDC guidelines and is no longer recommended as of 2015.7
Perhaps because revised trichomonas guidance is relatively
recent, awareness of trichomoniasis evaluation and diagnostic
guidelines in this study was significantly lower than for BV and
VVC. Not surprisingly, there was very poor adherence to
guidelines, with most patients (83%) who were evaluated for
trichomoniasis receiving a suboptimal workup. With tricho-
moniasis in particular, a failure of diagnosis has broad public
health implications because an accurate trichomoniasis diag-
nosis is critical for preventing transmission to new sex partners
and alerting existing partners about the need for treatment.7
The findings in this study add to the work of other inves-
tigators. A recent study conducted by Hillier et al regarding
diagnostic testing for vaginal discharge syndromes in prac-
tices affiliated with University of Pittsburgh revealed infre-
quent use of POC tests (15% vaginal pH, 21% KOH whiff test,
17% microscopy) in the evaluation of 303 women. The au-
thors found that 47% of women with a known infectious cause
of vaginitis received at least 1 inappropriate prescription and
that 34% who did not have an infectious cause incorrectly
received either an antifungal or an antibiotic agent.32 Some-
what higher, although still inadequate, rates of POC testing
were found in the much larger national sample in the present
study. Although this study was not intended to assess use of
treatments for vaginal infections, the study team feels that the
lack of accurate diagnostic testing in this population likely
also led to many cases of inappropriate treatment.
In this study cohort, partner therapy was confirmed in
only 59% of trichomoniasis-positive cases. Some physicians
in this study have adopted Expedited Partner Therapy and
provided a refill for the female patient’s prescription with-
out first examining her partner. Gaps in guideline adherence
also were found related to STI testing and follow-up visits
among trichomoniasis positive patients. One quarter of
trichomoniasis-positive patients were not tested for chla-
mydia and gonorrhea, and nearly 6 in 10 (58%) were not
tested for HIV, despite guideline recommendations.7 With
high documented reinfection rates, it is recommended that
trichomoniasis patients be rescreened within 3 months
after the completion of treatment.7,26 This study found
that fewer than half (47%) were rescreened within that
time frame, and nearly 4 in 10 (38%) never returned to be
rescreened.
Ultimately, 17% of the patients in this study study who re-
ceived a lab test (NAAT, BD Affirm/DNA Probe, Gram stain,
or culture) had a change from their initial vaginitis diagnosis.
Whether patients who did not receive a lab test may have had
their diagnosis changed if they had also received molecular lab
testing is unclear. Other published literature reports rates of
vaginitis mixed infection (at least 2 of BV, VVC, and tricho-
moniasis) ranging from 20% to 30%, and an increase in de-
tection of mixed infection with molecular lab testing.14,33–35
This study found a relatively low rate of mixed infection (11%)
in the total cohort, but also observed that use of molecular lab
testing was associated with a higher rate of diagnosed mixed
infection. Thus, it can be expected that at least some of the
patients who received POC-only workups in the patient cohort
had vaginitis diagnoses that were missed and likely would
have otherwise been caught with the use of lab-based testing.
Limitations
Because this study involved a survey approach and a
chart review by participating physicians, there were clearly
limitations. Despite a large physician sample (n = 333),
there may have been selection bias due to physician non-
response. Nevertheless, the even distribution of location in
the United States and years in practice suggests that a
fairly representative sample of physicians was obtained.
Interpretation of patient chart results assumes the physician
fully entered all information into the chart at the time of visits
and also pulled accurate and complete information from their
EHR at the time of chart audit completion. Asking physicians
to review their own notes within the EHR avoided the limi-
tations of claims database analyses. Study physicians were
instructed on how to randomly select patients based on ICD-9
or ICD-10 vaginitis diagnosis codes, in order to mitigate
patient-selection bias.
Examining the reliability of physician data entry from chart
records, the study team found that physicians sometimes used
test-type terminology interchangeably (eg, NAAT/PCR, cul-
ture, BD Affirm/DNA Probe and/or vaginitis panel). To aid in
the most accurate selection of the lab test evaluation method,
the team included example swab and vial images within the
online survey instrument. Even with this survey addition,
some physicians selected a test type inconsistent with their
other responses or within the open-ended description of the
patient’s workup. In order to improve data accuracy, data
cleaning was performed to adjust the lab test type selected
based on their summary responses within the survey.
Conclusion
For at least the past 2 decades, concerns have been raised
about the limited use of POC tests.19 Past studies have
shown that patient self-diagnosis and provider-based tele-
phone diagnosis are also inaccurate most of the time.16 Yet
during this same time period, providers have received clear
GUIDELINE ADHERENCE IN THE DIAGNOSIS OF VAGINITIS S-19
and consistent guidance to help correctly diagnose women
with vulvovaginal complaints. Study results strongly sug-
gest that those guidelines had little impact on patient care in
this cohort. Though this study was not intended to address
adverse complications of vaginitis, the study team feels that
many women with vulvovaginal complaints may unneces-
sarily suffer with persistent or recurrent symptoms because
of misdiagnoses. Providers should strongly consider turning
to other accurate, FDA-cleared diagnostic methods, such as
NAAT testing, the approach recommended in the recently
published ACOG Practice Bulletin on Vaginitis.2
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